JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RXDX
3251
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $2.33M | ﹤0.01% |
82,400
-527
| -0.6% | -$15.3K |
2021 Q2
4 quarters
|
|
|
VMEO
3252
DELISTED
Vimeo
VMEO
| $2.32M | ﹤0.01% |
385,903
+282,761
| +274% | +$2.56M |
2021 Q2
4 quarters
|
|
3253
ProShares Bitcoin Strategy ETF
BITO
$1.73B
| $2.32M | ﹤0.01% |
+200,000
| New | +$4.03M |
2022 Q2
0 quarters
|
|
|
NLSN
3254
PUT
DELISTED
Nielsen Holdings plc
NLSN
| $2.32M | ﹤0.01% |
100,000
-233,200
| -70% | -$5.97M |
2022 Q1
1 quarter
|
|
3255
PUT
Norfolk Southern
NSC
$71.3B
| $2.32M | ﹤0.01% |
10,200
-14,300
| -58% | -$3.51M |
2021 Q1
5 quarters
|
|
|
OPTU
3256
CALL
Optimum Communications Inc
OPTU
$349M
| $2.31M | ﹤0.01% |
250,000
| – | – |
2021 Q4
2 quarters
|
|
|
SOLN
3257
DELISTED
The Southern Company
SOLN
| $2.31M | ﹤0.01% |
43,653
-52,364
| -55% | -$2.88M |
2019 Q3
11 quarters
|
|
|
LGV
3258
DELISTED
Longview Acquisition Corp. II
LGV
| $2.31M | ﹤0.01% |
236,685
-513,482
| -68% | -$5.02M |
2021 Q3
3 quarters
|
|
|
AVDX
3259
DELISTED
AvidXchange
AVDX
| $2.31M | ﹤0.01% |
376,244
+352,056
| +1,455% | +$2.8M |
2021 Q4
2 quarters
|
|
3260
PUT
Legend Biotech
LEGN
$3.61B
| $2.31M | ﹤0.01% |
42,000
| – | – |
2022 Q1
1 quarter
|
|
|
GLDD
3261
DELISTED
Great Lakes Dredge & Dock
GLDD
| $2.31M | ﹤0.01% |
176,093
-155,482
| -47% | -$2.21M |
2016 Q4
22 quarters
|
|
|
KDNY
3262
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.31M | ﹤0.01% |
131,876
-1,274
| -1% | -$20K |
2015 Q2
28 quarters
|
|
|
NXH
3263
Neighborhood Intelligence Inc
NXH
$264M
| $2.31M | ﹤0.01% |
101,384
+46,702
| +85% | +$1.4M |
2017 Q4
18 quarters
|
|
3264
Janus Henderson B-BBB CLO ETF
JBBB
$1.52B
| $2.3M | ﹤0.01% |
+50,509
| New | +$2.41M |
2022 Q2
0 quarters
|
|
3265
Precigen
PGEN
$3.06B
| $2.3M | ﹤0.01% |
1,717,421
-36,887
| -2% | -$54.7K |
2013 Q3
35 quarters
|
|
3266
Rackspace Technology
RXT
$1.05B
| $2.3M | ﹤0.01% |
321,062
+194,961
| +155% | +$1.76M |
2020 Q3
7 quarters
|
|
|
MFA
3267
MFA Financial
MFA
$773M
| $2.29M | ﹤0.01% |
213,411
-347,582
| -62% | -$4.68M |
2013 Q2
36 quarters
|
|
3268
LegalZoom.com
LZ
$959M
| $2.29M | ﹤0.01% |
208,490
+190,608
| +1,066% | +$2.52M |
2021 Q2
4 quarters
|
|
|
BSLK
3269
DELISTED
Bolt Projects Holdings
BSLK
| $2.29M | ﹤0.01% |
11,693
-2,576
| -18% | -$503K |
2021 Q2
4 quarters
|
|
|
SCU
3270
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $2.28M | ﹤0.01% |
273,690
-278,810
| -50% | -$3.07M |
2013 Q2
36 quarters
|
|
3271
iPath Bloomberg Commodity Index Total Return ETN due 12 June 2036
DJP
$871M
| $2.28M | ﹤0.01% |
65,542
+62
| +0.1% | +$2.4K |
2013 Q2
36 quarters
|
|
3272
Kimbell Royalty Partners
KRP
$1.47B
| $2.28M | ﹤0.01% |
145,308
+119,283
| +458% | +$2.07M |
2019 Q1
13 quarters
|
|
3273
Invesco Solar ETF
TAN
$903M
| $2.28M | ﹤0.01% |
31,877
-43,747
| -58% | -$3.03M |
2017 Q2
20 quarters
|
|
|
CTXS
3274
PUT
DELISTED
Citrix Systems Inc
CTXS
| $2.27M | ﹤0.01% |
+23,400
| New | +$2.33M |
2022 Q2
0 quarters
|
|
3275
Astrana Health
ASTH
$1.78B
| $2.27M | ﹤0.01% |
58,862
+5,303
| +10% | +$202K |
2018 Q2
16 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.